Navigation Links
Roche Symposium Showcases Accomplishments of Next Generation of Chemists
Date:5/14/2008

- Outstanding Graduate Students and Professors Honored for Their Research -

PALO ALTO, Calif., May 14 /PRNewswire/ -- Roche has honored 12 outstanding Ph.D. students and two professors with the company's Excellence in Chemistry Award for research accomplishments in the field of organic chemistry. The winners participated in Roche's annual Chemistry Symposium where they gained a real-world perspective on the important role of organic chemistry in pharmaceutical discovery. This year's fifth annual symposium was held in Palo Alto on May 12 and 13. The event rotates annually between Roche research centers in Nutley, New Jersey, and Palo Alto, California.

"The Chemistry Symposium is a bridge between cutting-edge researchers in academia and at Roche and is intended to honor the accomplishments of the awardees and to demonstrate the importance of chemistry in creating new medicines," said Eric Sjogren, Ph.D., vice president, Roche Medicinal Chemistry. "We hope that this next generation of chemists leaves with a deeper understanding of the vital role organic chemistry plays in the pharmaceutical industry."

During the symposium, students discussed their research projects and were given overviews of the drug discovery process by Roche scientists. In addition, there were plenary lectures by this year's faculty award winners: Professor Jeffrey W. Bode of the University of Pennsylvania and Professor Dirk Trauner of the University of California, Berkeley. The awardees also heard case histories in medicinal and process chemistry and were given a tour of the Roche Palo Alto site.

Representing a range of prestigious institutions, the 12 winners this year were: Melissa Beenen (University of California, Berkeley), Landy K. Blasdel (Harvard University), Mark S. Chen (University of Illinois at Urbana-Champaign), John A. Enquist, Jr. (California Institute of Technology), Kami L. Hull (University of Michigan), Thomas J. Maimone (The Scripps Research Institute), Meredeth A. McGowan (Harvard University), Joshua G. Pierce (University of Pittsburgh), Nathan D. Shapiro (University of California, Berkeley), Eduardas Skucas (University of Texas at Austin), Vladimir Sofiyev (University of California, Berkeley), and Nicole White (University of California, Irvine).

The students were chosen by Roche chemists in Palo Alto and Nutley through a rigorous selection process. More than 45 faculty members at prominent U.S. universities were invited to nominate students to participate in the symposium. Professors were asked to consider students who might be interested in the pharmaceutical industry and who are one to two years from completing their Ph.D. The submissions required a supporting letter from the nominee, the student's resume and a short research summary. Besides the opportunity to attend and present their research projects at the Chemistry Symposium, the students each received a crystal award and an honorarium. Professors Bode and Trauner each received an unrestricted grant to support their ongoing research in addition to the honorarium.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. Located in Palo Alto, Calif., Roche Palo Alto LLC is one of the company's six pharmaceutical research centers. Here scientists focus on the discovery and early clinical development of innovative new medicines to treat inflammatory, respiratory and viral diseases. For more information on Roche, access http://www.roche.com or http://www.rocheusa.com.

Contact(s): Jacqueline Wallach Darien Wilson

650-855-6228 973-562-2232


'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Roches Vidal Honored as 2008 HBA Rising Star
2. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
3. Media advisory - Neurochems Annual and Special Meeting of Shareholders April 15, 2008
4. Neurochem Annual and Special Meeting of shareholders
5. Rochester Medical Applauds Improved U.S. Medicare Coverage Policy for Intermittent Catheters
6. Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
7. Roche Statement Regarding Tamiflu U.S. Label Revision
8. Neurochem announces departure of two members of management team
9. Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
10. Press Statement: Roche Affirms That Tamiflu(R) is in Ample Supply Nationwide
11. Roche Completes Tender Offer for Ventana Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... Swirl: A Wine Tasting Event in New York City, with long-time partners The ...
(Date:12/4/2016)... ... ... While James Earl Jones is known for myriad roles on stage and ... Page". One of the forthcoming episodes examines mammogram techniques; a very important part of ... due to early detection. Like any other disease, treatments have a much higher chance ...
(Date:12/4/2016)... , ... December 03, 2016 , ... ... growing Entrepreneurial Company in the Dallas area” Tuesday evening at the 26th Annual ... Hotel, presented by SMU's Cox School’s Caruth Institute for Entrepreneurship. Dallas 100™, co-founded ...
(Date:12/4/2016)... Newport Beach, CA (PRWEB) , ... December 04, ... ... youthful appearance without undergoing major cosmetic surgery can now take advantage of a ... is an advanced skin rejuvenation treatment that reduces the appearance of age spots, ...
(Date:12/4/2016)... ... December 04, 2016 , ... Responsible dental care hinges ... brush properly to achieve optimal results. This important necessity inspired an inventor from Las ... a way to ensure that people break or avoid bad techniques of brushing the ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... Blueprint Medicines Corporation (NASDAQ: BPMC ... kinase medicines for patients with genomically defined diseases, ... trial evaluating BLU-285, an investigational medicine for the ... Blueprint Medicines is developing BLU-285 as a potent, ... 90 to 95 percent of patients with SM ...
(Date:12/4/2016)... HANOVER, N.J. , Dec. 3, 2016  Results ... (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the median ... 45.3% compared to placebo (1.63 vs 2.98, p=0.010) in ... today announced that the data are being featured in ... American Society of Hematology (ASH) Annual Meeting and presented ...
(Date:12/2/2016)... - bioLytical lanza el INSTI HIV Self Test para el mercado africano ... Continue Reading ... New: INSTI Self Test! (PRNewsFoto/bioLytical ... bioLytical Laboratories (la "Compañía"), un líder mundial en ... de su INSTI HIV Self Test  a África con una versión de menor ...
Breaking Medicine Technology: